The cardioprotective effects of mineralocorticoid receptor antagonists

Pharmacology and Therapeutics

Volumn 142, Issue 1, 2014, Pages 72-87

  Van Den Berg, T N A ^a   Rongen, Gerard A ^a   Fröhlich, Georg M ^b   Deinum, Jaap ^a   Hausenloy, Derek J ^b   Riksen, Niels P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Aldosterone; Antagonist; Cardiac remodeling; Ischemia reperfusion injury; Mineralocorticoid receptor; Myocardium

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ADENOSINE RECEPTOR; ALDOSTERONE; CORTISONE; HYDROCORTISONE; MINERALOCORTICOID ANTAGONIST;

ACUTE DRUG ADMINISTRATION; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CORONARY REPERFUSION; GENOMICS; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; INTRACELLULAR SIGNALING; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; SCAR FORMATION;

ALDOSTERONE; ANTAGONIST; CARDIAC REMODELING; ISCHEMIA-REPERFUSION INJURY; MINERALOCORTICOID RECEPTOR; MYOCARDIUM;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR SYSTEM; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIAL REPERFUSION INJURY; RECEPTORS, MINERALOCORTICOID;

EID: 84896737736     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.11.006     Document Type: Review

References (171)

1. A.K. Abiose, G.A. Mansoor, M. Barry, R. Soucier, C.K. Nair, and D. Hager Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy Am J Cardiol 93 2004 1564 1566
2. A.K. Agarwal, F.M. Rogerson, T. Mune, and P.C. White Analysis of the human gene encoding the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase J Steroid Biochem Mol Biol 55 1995 473 479
3. A.L. Albiston, V.R. Obeyesekere, R.E. Smith, and Z.S. Krozowski Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme Mol Cell Endocrinol 105 1994 R11 R17
4. A. Anzai, T. Anzai, S. Nagai, Y. Maekawa, K. Naito, and H. Kaneko et al. Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling Circulation 125 2012 1234 1245
5. F. Atalar, B. Vural, C. Ciftci, A. Demirkan, G. Akan, and B. Susleyici-Duman et al. 11beta-hydroxysteroid dehydrogenase type 1 gene expression is increased in ascending aorta tissue of metabolic syndrome patients with coronary artery disease Genet Mol Res 11 2012 3122 3132
6. S.R. Bapoje, A. Bahia, J.E. Hokanson, P.N. Peterson, P.A. Heidenreich, and J. Lindenfeld et al. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials Circ Heart Fail 6 2013 166 173
7. J.C. Barbato, P.J. Mulrow, J.I. Shapiro, and R. Franco-Saenz Rapid effects of aldosterone and spironolactone in the isolated working rat heart Hypertension 40 2002 130 135
8. C.S. Barr, C.C. Lang, J. Hanson, M. Arnott, N. Kennedy, and A.D. Struthers Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease Am J Cardiol 76 1995 1259 1265
9. A.T. Beggah, B. Escoubet, S. Puttini, S. Cailmail, V. Delage, and A. Ouvrard-Pascaud et al. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes Proc Natl Acad Sci USA 99 2002 7160 7165
10. F. Beygui, J.P. Collet, J.J. Benoliel, N. Vignolles, R. Dumaine, and O. Barthelemy et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction Circulation 114 2006 2604 2610
11. F. Beygui, G. Montalescot, E. Vicaut, S. Rouanet, E. Van Belle, and C. Baulac et al. Aldosterone and long-term outcome after myocardial infarction: a substudy of the french nationwide Observatoire sur la Prise en charge hospitaliere, l'Evolution a un an et les caRacteristiques de patients presentant un infArctus du myocarde avec ou sans onde Q (OPERA) study Am Heart J 157 2009 680 687
12. L.A. Bienvenu, J. Morgan, A.J. Rickard, G.H. Tesch, G.A. Cranston, and E.K. Fletcher et al. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis Endocrinology 153 2012 3416 3425
13. A.S. Brem, R.B. Bina, T. King, and D.J. Morris Bidirectional activity of 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle cells Steroids 60 1995 406 410
14. A.S. Brem, R.B. Bina, T.C. King, and D.J. Morris Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells Hypertension 31 1998 459 462
15. P.S. Brereton, R.R. van Driel, F. Suhaimi, K. Koyama, R. Dilley, and Z. Krozowski Light and electron microscopy localization of the 11beta- hydroxysteroid dehydrogenase type I enzyme in the rat Endocrinology 142 2001 1644 1651
16. R.W. Brown, R. Diaz, A.C. Robson, Y.V. Kotelevtsev, J.J. Mullins, and M.H. Kaufman et al. The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development Endocrinology 137 1996 794 797
17. J.G. Burniston, A. Saini, L.B. Tan, and D.F. Goldspink Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo J Mol Cell Cardiol 39 2005 395 399
18. G.E. Callera, R.M. Touyz, R.C. Tostes, A. Yogi, Y. He, and S. Malkinson et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src Hypertension 45 2005 773 779
19. W. Chai, I.M. Garrelds, U. Arulmani, R.G. Schoemaker, J.M. Lamers, and A.H. Danser Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? Br J Pharmacol 145 2005 664 671
20. W. Chai, I.M. Garrelds, R. de Vries, and A.H. Danser Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? Hypertension 47 2006 665 670
21. M. Christ, K. Douwes, C. Eisen, G. Bechtner, K. Theisen, and M. Wehling Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells Hypertension 25 1995 117 123
22. M. Christ, A. Gunther, M. Heck, B.M. Schmidt, E. Falkenstein, and M. Wehling Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells Circulation 99 1999 1485 1491
23. T.Y. Chun, L. Bloem, and J.H. Pratt Spironolactone increases integrin beta3 gene expression in kidney and heart muscle cells Mol Cell Endocrinol 194 2002 175 182
24. A. Cittadini, C. Casaburi, M.G. Monti, A. Di Gianni, R. Serpico, and G. Scherillo et al. Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure Cardiovasc Drugs Ther 16 2002 195 201
25. J. Condon, M.L. Ricketts, C.B. Whorwood, and P.M. Stewart Ontogeny and sexual dimorphic expression of mouse type 2 11beta-hydroxysteroid dehydrogenase Mol Cell Endocrinol 127 1997 121 128
26. R. Dabrowski, and H. Szwed Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation Cardiol J 19 2012 223 229
27. N. De Angelis, F. Fiordaliso, R. Latini, L. Calvillo, M. Funicello, and M. Gobbi et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat J Mol Cell Cardiol 34 2002 1655 1665
28. P. De-An, L. Li, X. Zhi-Yun, H. Jin-Yu, X. Zheng-Ming, and W. Min et al. Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation Clin Cardiol 33 2010 23 29
29. J.A. Delyani, E.L. Robinson, and A.E. Rudolph Effect of a selective aldosterone receptor antagonist in myocardial infarction Am J Physiol Heart Circ Physiol 281 2001 H647 H654
30. G.A. Deuchar, D. McLean, P.W. Hadoke, D.G. Brownstein, D.J. Webb, and J.J. Mullins et al. 11beta-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice Endocrinology 152 2011 236 246
31. A.M. Dorrance, H.L. Osborn, R. Grekin, and R.C. Webb Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats Am J Physiol Regul Integr Comp Physiol 281 2001 R944 R950
32. F. Edelmann, R. Wachter, A.G. Schmidt, E. Kraigher-Krainer, C. Colantonio, and W. Kamke et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial JAMA 309 2013 781 791
33. S. Enomoto, M. Yoshiyama, T. Omura, R. Matsumoto, T. Kusuyama, and S. Kim et al. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction Heart 91 2005 1595 1600
34. N. Farman, and B. Bocchi Mineralocorticoid selectivity: molecular and cellular aspects Kidney Int 57 2000 1364 1369
35. C.A. Farquharson, and A.D. Struthers Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure Circulation 101 2000 594 597
36. D. Fraccarollo, S. Berger, P. Galuppo, S. Kneitz, L. Hein, and G. Schutz et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction Circulation 123 2011 400 408
37. D. Fraccarollo, P. Galuppo, S. Hildemann, M. Christ, G. Ertl, and J. Bauersachs Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction J Am Coll Cardiol 42 2003 1666 1673
38. D. Fraccarollo, P. Galuppo, I. Schmidt, G. Ertl, and J. Bauersachs Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction Cardiovasc Res 67 2005 97 105
39. D. Fraccarollo, P. Galuppo, S. Schraut, S. Kneitz, N. van Rooijen, and G. Ertl et al. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response Hypertension 51 2008 905 914
40. R.A. Frieler, H. Meng, S.Z. Duan, S. Berger, G. Schutz, and Y. He et al. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia Stroke 42 2011 179 185
41. N. Fujimura, K. Noma, T. Hata, J. Soga, T. Hidaka, and N. Idei et al. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension Clin Pharmacol Ther 91 2012 289 297
42. M. Fujita, T. Minamino, H. Asanuma, S. Sanada, A. Hirata, and M. Wakeno et al. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts Hypertension 46 2005 113 117
43. P.J. Fuller, Y. Yao, J. Yang, and M.J. Young Mechanisms of ligand specificity of the mineralocorticoid receptor J Endocrinol 213 2012 15 24
44. P.J. Fuller, and M.J. Young Mechanisms of mineralocorticoid action Hypertension 46 2005 1227 1235
45. J.W. Funder Mineralocorticoid receptors: distribution and activation Heart Fail Rev 10 2005 15 22
46. J.W. Funder, P.T. Pearce, R. Smith, and J. Campbell Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors Endocrinology 125 1989 2224 2226
47. F. Galetta, G. Bernini, F. Franzoni, A. Bacca, I. Fivizzani, and L. Tocchini et al. Cardiac remodeling in patients with primary aldosteronism J Endocrinol Invest 32 2009 739 745
48. X. Gao, L. Peng, C.M. Adhikari, J. Lin, and Z. Zuo Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure J Card Fail 13 2007 170 177
49. R. Goldkorn, A. Yurenev, J. Blumenfeld, D. Fishman, and R.B. Devereux Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension Am J Hypertens 15 2002 340 345
50. N. Golestaneh, S. Picaud, and M. Mirshahi The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity Mol Vis 8 2002 221 225
51. E.P. Gomez-Sanchez, N. Ahmad, D.G. Romero, and C.E. Gomez-Sanchez Origin of aldosterone in the rat heart Endocrinology 145 2004 4796 4802
52. E.P. Gomez-Sanchez, M.T. Venkataraman, D. Thwaites, and C. Fort ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension Am J Physiol 258 1990 E649 E653
53. L. Gullestad, T. Ueland, L.E. Vinge, A. Finsen, A. Yndestad, and P. Aukrust Inflammatory cytokines in heart failure: mediators and markers Cardiology 122 2012 23 35
54. H. Hatakeyama, S. Inaba, and I. Miyamori 11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension Hypertension 33 1999 1179 1184
55. D.J. Hausenloy, and D.M. Yellon Preconditioning and postconditioning: united at reperfusion Pharmacol Ther 116 2007 173 191
56. D.J. Hausenloy, and D.M. Yellon Preconditioning and postconditioning: underlying mechanisms and clinical application Atherosclerosis 204 2009 334 341
57. M. Hayashi, T. Tsutamoto, A. Wada, T. Tsutsui, C. Ishii, and K. Ohno et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction Circulation 107 2003 2559 2565
58. J.P. Herman, P.D. Patel, H. Akil, and S.J. Watson Localization and regulation of glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal formation of the rat Mol Endocrinol 3 1989 1886 1894
59. A.A. Herrada, F.J. Contreras, N.P. Marini, C.A. Amador, P.A. Gonzalez, and C.M. Cortes et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity J Immunol 184 2010 191 202
60. B.S. Huang, and F.H. Leenen Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI Am J Physiol Heart Circ Physiol 288 2005 H2491 H2497
61. K. Ishizawa, Y. Izawa, H. Ito, C. Miki, K. Miyata, and Y. Fujita et al. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation Hypertension 46 2005 1046 1052
62. J. Iwanami, M. Mogi, S. Okamoto, X.Y. Gao, J.M. Li, and Min et al. Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model Eur J Pharmacol 566 2007 153 159
63. H.V. Joffe, R.Y. Kwong, M.D. Gerhard-Herman, C. Rice, K. Feldman, and G.K. Adler Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus J Clin Endocrinol Metab 92 2007 2552 2558
64. R.M. Kanashiro-Takeuchi, B. Heidecker, G. Lamirault, J.W. Dharamsi, and J.M. Hare Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction Clin Transl Sci 2 2009 2009 134 142
65. Y.M. Kang, Z.H. Zhang, R.F. Johnson, Y. Yu, T. Beltz, and A.K. Johnson et al. Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure Circ Res 99 2006 758 766
66. S. Keidar, T. Hayek, M. Kaplan, E. Pavlotzky, S. Hamoud, and R. Coleman et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice J Cardiovasc Pharmacol 41 2003 955 963
67. T. Kisaka, R. Ozono, T. Ishida, Y. Higashi, T. Oshima, and Y. Kihara Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension J Hypertens 30 2012 2322 2330
68. P. Klusonova, M. Kucka, P. Ergang, I. Miksik, J. Bryndova, and J. Pacha Cloning of chicken 11beta-hydroxysteroid dehydrogenase type 1 and its tissue distribution J Steroid Biochem Mol Biol 111 2008 217 224
69. P. Klusonova, L. Rehakova, G. Borchert, K. Vagnerova, J. Neckar, and P. Ergang et al. Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart Endocrinology 150 2009 4270 4277
70. N. Kobayashi, H. Fukushima, H. Takeshima, W. Koguchi, Y. Mamada, and H. Hirata et al. Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb Am J Hypertens 23 2010 1007 1013
71. N. Kobayashi, K. Hara, A. Tojo, M.L. Onozato, T. Honda, and K. Yoshida et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway Hypertension 45 2005 538 544
72. M. Konermann, B.M. Sanner, J. Grotz, F. Laschewski, W. Josephs, and H.J. Odenthal et al. Effect of infarct size and site, patency of the infarct vessel and perfusion of vital myocardium on remodeling of the left ventricle - studies with cine-magnetic resonance tomography in the first 6 months following myocardial infarct Z Kardiol 85 1996 906 916
73. L. Kornel Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells Am J Hypertens 7 1994 100 103
74. Z. Krozowski, S. Stuchbery, P. White, C. Monder, and J.W. Funder Characterization of 11 beta-hydroxysteroid dehydrogenase gene expression: identification of multiple unique forms of messenger ribonucleic acid in the rat kidney Endocrinology 127 1990 3009 3013
75. H. Krum, H. Shi, B. Pitt, J. McMurray, K. Swedberg, and D.J. van Veldhuisen et al. Clinical benefit of Eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study Circ Heart Fail 6 4 2013 Jul 711 718
76. A. Lal, J.P. Veinot, and F.H. Leenen Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats Cardiovasc Res 64 2004 437 447
77. C. Lammers, T. Dartsch, M.C. Brandt, D. Rottlander, M. Halbach, and G. Peinkofer et al. Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat Cell Physiol Biochem 29 2012 833 840
78. R. Laszlo, K. Bentz, A. Konior, C. Eick, B. Schreiner, and K. Kettering et al. Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits Naunyn Schmiedebergs Arch Pharmacol 382 2010 347 356
79. X. Li, Y. Qi, Y. Li, S. Zhang, S. Guo, and S. Chu et al. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials Circ Heart Fail 6 2013 156 165
80. K.X. Li, R.E. Smith, P. Ferrari, J.W. Funder, and Z.S. Krozowski Rat 11 beta-hydroxysteroid dehydrogenase type 2 enzyme is expressed at low levels in the placenta and is modulated by adrenal steroids in the kidney Mol Cell Endocrinol 120 1996 67 75
81. Y.H. Lin, H.H. Lee, K.L. Liu, J.K. Lee, S.R. Shih, and S.C. Chueh et al. Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy Surgery 150 2011 526 533
82. Y. Liu, K. Hirooka, A. Nishiyama, B. Lei, T. Nakamura, and T. Itano et al. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury Exp Eye Res 96 2012 116 123
83. T.Y. Loan Le, M. Mardini, V.M. Howell, J.W. Funder, A.W. Ashton, and A.S. Mihailidou Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction Hypertension 59 2012 1164 1169
84. M. Lombes, N. Alfaidy, E. Eugene, A. Lessana, N. Farman, and J.P. Bonvalet Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart Circulation 92 1995 175 182
85. M. Lombes, S. Kenouch, A. Souque, N. Farman, and M.E. Rafestin-Oblin The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase Endocrinology 135 1994 834 840
86. M. Lombes, M.E. Oblin, J.M. Gasc, E.E. Baulieu, N. Farman, and J.P. Bonvalet Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor Circ Res 71 1992 503 510
87. R. Losel, M. Feuring, and M. Wehling Non-genomic aldosterone action: from the cell membrane to human physiology J Steroid Biochem Mol Biol 83 2002 167 171
88. J.E. Macdonald, N. Kennedy, and A.D. Struthers Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment Heart 90 2004 765 770
89. A. Mano, T. Tatsumi, J. Shiraishi, N. Keira, T. Nomura, and M. Takeda et al. Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways Circulation 110 2004 317 323
90. P.G. Masci, J. Ganame, M. Francone, W. Desmet, V. Lorenzoni, and I. Iacucci et al. Relationship between location and size of myocardial infarction and their reciprocal influences on post-infarction left ventricular remodelling Eur Heart J 32 2011 1640 1648
91. S. Masson, L. Staszewsky, G. Annoni, E. Carlo, B. Arosio, and A. Bai et al. Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction J Card Fail 10 2004 433 441
92. S. Matsui, H. Satoh, H. Kawashima, S. Nagasaka, C.F. Niu, and T. Urushida et al. Non-genomic effects of aldosterone on intracellular ion regulation and cell volume in rat ventricular myocytes Can J Physiol Pharmacol 85 2007 264 273
93. R. Matsumoto, M. Yoshiyama, T. Omura, S. Kim, Y. Nakamura, and Y. Izumi et al. Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction Circ J 68 2004 376 382
94. K. Mazancova, M. Kopecky, I. Miksik, and J. Pacha 11beta-hydroxysteroid dehydrogenase in the heart of normotensive and hypertensive rats J Steroid Biochem Mol Biol 94 2005 273 277
95. J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Bohm, and Dickstein et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
96. J.M. Mejia-Vilet, V. Ramirez, C. Cruz, N. Uribe, G. Gamba, and N.A. Bobadilla Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone Am J Physiol Renal Physiol 293 2007 F78 F86
97. A.S. Mihailidou, K.A. Buhagiar, and H.H. Rasmussen Na + influx and Na(+)-K+ pump activation during short-term exposure of cardiac myocytes to aldosterone Am J Physiol 274 1998 C175 C181
98. A.S. Mihailidou, T.Y. Loan Le, M. Mardini, and J.W. Funder Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction Hypertension 54 2009 1306 1312
99. J.G. Mill, C. Milanez Mda, M.M. de Resende, G. Gomes Mda, and C.M. Leite Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats Clin Exp Pharmacol Physiol 30 2003 739 744
100. P. Milliez, N. Deangelis, C. Rucker-Martin, A. Leenhardt, E. Vicaut, and E. Robidel et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction Eur Heart J 26 2005 2193 2199
101. P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, and J.J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J Am Coll Cardiol 45 2005 1243 1248
102. X.L. Moore, I. Hoong, and T.J. Cole Expression of the 11beta-hydroxysteroid dehydrogenase 2 gene in the mouse Kidney Int 57 2000 1307 1312
103. P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, and C. Monteil et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone Eur Heart J 29 2008 2171 2179
104. A. Naray-Fejes-Toth, and G. Fejes-Toth Extranuclear localization of endogenous 11beta-hydroxysteroid dehydrogenase-2 in aldosterone target cells Endocrinology 139 1998 2955 2959
105. J.A. Nehme, P. Lacolley, C. Labat, P. Challande, E. Robidel, and C. Perret et al. Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure J Mol Cell Cardiol 39 2005 511 519
106. S. Neumann, K. Huse, R. Semrau, A. Diegeler, R. Gebhardt, and G.H. Buniatian et al. Aldosterone and d-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro Hypertension 39 2002 756 760
107. K. Noda, M. Kobara, J. Hamada, Y. Yoshifuji, T. Shiraishi, and T. Tanaka et al. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts J Cardiovasc Pharmacol 60 2012 140 149
108. A. Odermatt, and A.G. Atanasov Mineralocorticoid receptors: emerging complexity and functional diversity Steroids 74 2009 163 171
109. A. Odermatt, and D.V. Kratschmar Tissue-specific modulation of mineralocorticoid receptor function by 11beta-hydroxysteroid dehydrogenases: an overview Mol Cell Endocrinol 350 2012 168 186
110. L. Pascual-Le Tallec, F. Simone, S. Viengchareun, G. Meduri, M.J. Thirman, and M. Lombes The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions Mol Endocrinol 19 2005 1158 1169
111. E. Perrier, B.G. Kerfant, N. Lalevee, P. Bideaux, M.F. Rossier, and S. Richard et al. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction Circulation 110 2004 776 783
112. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, and B. Roniker et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
113. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, and A. Perez et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
114. S. Rajagopalan, D. Duquaine, S. King, B. Pitt, and P. Patel Mineralocorticoid receptor antagonism in experimental atherosclerosis Circulation 105 2002 2212 2216
115. F.J. Ramires, A. Mansur, O. Coelho, M. Maranhao, C.J. Gruppi, and C. Mady et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy Am J Cardiol 85 2000 1207 1211
116. V. Ramirez, J. Trujillo, R. Valdes, N. Uribe, C. Cruz, and G. Gamba et al. Adrenalectomy prevents renal ischemia-reperfusion injury Am J Physiol Renal Physiol 297 2009 F932 F942
117. A. Raz-Pasteur, A. Gamliel-Lazarovich, A. Gantman, R. Coleman, and S. Keidar Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice J Renin Angiotensin Aldosterone Syst 2012 Dec 6 [Epub ahead of print]
118. A. Rochetaing, C. Chapon, L. Marescaux, A. Le Bouil, A. Furber, and P. Kreher Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats Can J Physiol Pharmacol 81 2003 864 872
119. B.L. Roland, and J.W. Funder Localization of 11beta-hydroxysteroid dehydrogenase type 2 in rat tissues: in situ studies Endocrinology 137 1996 1123 1128
120. D.G. Romero, M. Zhou, and C.E. Gomez-Sanchez Cloning and expression of the bovine 11beta-hydroxysteroid dehydrogenase type-2 J Steroid Biochem Mol Biol 72 2000 231 237
121. R. Rossi, A. Nuzzo, D. Iaccarino, A. Lattanzi, G. Origliani, and D.E. Monopoli et al. Effects of antihypertensive treatment on endothelial function in postmenopausal hypertensive women. A significant role for aldosterone inhibition J Renin Angiotensin Aldosterone Syst 12 2011 446 455
122. G.P. Rossi, A. Sacchetto, E. Pavan, P. Palatini, G.R. Graniero, and C. Canali et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma Circulation 95 1997 1471 1478
123. K. Sanchez-Pozos, J. Barrera-Chimal, J. Garzon-Muvdi, R. Perez-Villalva, R. Rodriguez-Romo, and C. Cruz et al. Recovery from ischemic acute kidney injury by spironolactone administration Nephrol Dial Transplant 27 2012 3160 3169
124. D. Sanz-Rosa, M.P. Oubina, E. Cediel, N. De las Heras, P. Aragoncillo, and G. Balfagon et al. Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences Antioxid Redox Signal 7 2005 1294 1301
125. C.L. Sartorio, D. Fraccarollo, P. Galuppo, M. Leutke, G. Ertl, and I. Stefanon et al. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction Hypertension 50 2007 919 925
126. A. Schafer, C. Vogt, D. Fraccarollo, J. Widder, U. Flierl, and S.K. Hildemann et al. Eplerenone improves vascular function and reduces platelet activation in diabetic rats J Physiol Pharmacol 61 2010 45 52
127. B.M. Schmidt, A.C. Georgens, N. Martin, H.C. Tillmann, M. Feuring, and M. Christ et al. Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system J Clin Endocrinol Metab 86 2001 761 767
128. B.M. Schmidt, K. Horisberger, M. Feuring, A. Schultz, and M. Wehling Aldosterone blunts human baroreflex sensitivity by a nongenomic mechanism Exp Clin Endocrinol Diabetes 113 2005 252 256
129. K. Schmidt, R. Tissier, B. Ghaleh, T. Drogies, S.B. Felix, and T. Krieg Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion Eur Heart J 31 2010 1655 1662
130. M. Schmitt, P. Gunaruwan, and M.P. Frenneaux Rapid nongenomic aldosterone effects in the human forearm? Hypertension 43 2004 (e1; author reply e2)
131. M. Schneider, A. Ulsenheimer, M. Christ, and M. Wehling Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells Am J Physiol 272 1997 E616 E620
132. S.W. Schneider, Y. Yano, B.E. Sumpio, B.P. Jena, J.P. Geibel, and M. Gekle et al. Rapid aldosterone-induced cell volume increase of endothelial cells measured by the atomic force microscope Cell Biol Int 21 1997 759 768
133. J.R. Seckl, K.L. Dickson, C. Yates, and G. Fink Distribution of glucocorticoid and mineralocorticoid receptor messenger RNA expression in human postmortem hippocampus Brain Res 561 1991 332 337
134. K.E. Sheppard, and D.J. Autelitano 11beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart Endocrinology 143 2002 198 204
135. G. Shi, Y. Fu, W. Jiang, A. Yin, M. Feng, and Y. Wu et al. Activation of Src-ATF1 pathway is involved in upregulation of Nox1, a catalytic subunit of NADPH oxidase, by aldosterone Endocr J 58 2011 491 499
136. J.S. Silvestre, C. Heymes, A. Oubenaissa, V. Robert, B. Aupetit-Faisant, and A. Carayon et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis Circulation 99 1999 2694 2701
137. O. Skott, T.R. Uhrenholt, J. Schjerning, P.B. Hansen, L.E. Rasmussen, and B.L. Jensen Rapid actions of aldosterone in vascular health and disease - friend or foe? Pharmacol Ther 111 2006 495 507
138. S.H. Slight, V.K. Ganjam, C.E. Gomez-Sanchez, M.Y. Zhou, and K.T. Weber High affinity NAD(+)-dependent 11 beta-hydroxysteroid dehydrogenase in the human heart J Mol Cell Cardiol 28 1996 781 787
139. S. Slight, V.K. Ganjam, D.J. Nonneman, and K.T. Weber Glucocorticoid metabolism in the cardiac interstitium: 11 beta-hydroxysteroid dehydrogenase activity in cardiac fibroblasts J Lab Clin Med 122 1993 180 187
140. S. Slight, V.K. Ganjam, and K.T. Weber Species diversity of 11 beta-hydroxysteroid dehydrogenase in the cardiovascular system J Lab Clin Med 124 1994 821 826
141. R.E. Smith, and Z.S. Krozowski 11 beta-hydroxysteroid dehydrogenase type I enzyme in the hearts of normotensive and spontaneously hypertensive rats Clin Exp Pharmacol Physiol 23 1996 642 647
142. R.E. Smith, P.J. Little, J.A. Maguire, A.N. Stein-Oakley, and Z.S. Krozowski Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme Clin Exp Pharmacol Physiol 23 1996 549 551
143. G.W. Souness, A.S. Brem, and D.J. Morris 11 beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism Steroids 67 2002 195 201
144. M. Stowasser, J. Sharman, R. Leano, R.D. Gordon, G. Ward, and D. Cowley et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I J Clin Endocrinol Metab 90 2005 5070 5076
145. K.B. Studen, M. Sebestjen, M. Pfeifer, and J. Prezelj Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome Eur J Endocrinol 164 2011 389 395
146. J. Suzuki, M. Iwai, M. Mogi, A. Oshita, T. Yoshii, and J. Higaki et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by
147. G. Suzuki, H. Morita, T. Mishima, V.G. Sharov, A. Todor, and E.J. Tanhehco et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure Circulation 106 2002 2967 2972
148. K. Swedberg, F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, and H. Shi et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study J Am Coll Cardiol 59 2012 1598 1603
149. A. Syngle, K. Vohra, L. Kaur, and S. Sharma Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis Scand J Rheumatol 38 2009 15 22
150. S. Takai, D. Jin, M. Muramatsu, K. Kirimura, H. Sakonjo, and M. Miyazaki Eplerenone inhibits atherosclerosis in nonhuman primates Hypertension 46 2005 1135 1139
151. Y. Takeda Pathophysiological roles of vascular 11beta-hydroxysteroid dehydrogenase and aldosterone J Steroid Biochem Mol Biol 85 2003 443 447
152. M. Takeda, T. Tatsumi, S. Matsunaga, H. Hayashi, M. Kimata, and S. Honsho et al. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts Hypertens Res 30 2007 427 437
153. A. Thompson, V.K. Han, and K. Yang Differential expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 mRNA and glucocorticoid receptor protein during mouse embryonic development J Steroid Biochem Mol Biol 88 2004 367 375
154. N. Toda, S. Nakanishi, and S. Tanabe Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications Br J Pharmacol 168 2013 519 533
155. J.W. Tomlinson, E.A. Walker, I.J. Bujalska, N. Draper, G.G. Lavery, and M.S. Cooper et al. 11beta-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response Endocr Rev 25 2004 831 866
156. J.H. van Berlo, M. Maillet, and J.D. Molkentin Signaling effectors underlying pathologic growth and remodeling of the heart J Clin Invest 123 2013 37 45
157. S.W. van den Borne, J. Diez, W.M. Blankesteijn, J. Verjans, L. Hofstra, and J. Narula Myocardial remodeling after infarction: the role of myofibroblasts Nat Rev Cardiol 7 2010 30 37
158. B.R. Walker, J.C. Campbell, B.C. Williams, and C.R. Edwards Tissue-specific distribution of the NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase Endocrinology 131 1992 970 972
159. B.R. Walker, J.L. Yau, L.P. Brett, J.R. Seckl, C. Monder, and B.C. Williams et al. 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids Endocrinology 129 1991 3305 3312
160. Q. Wang, S. Clement, G. Gabbiani, J.D. Horisberger, M. Burnier, and B.C. Rossier et al. Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet Am J Physiol Renal Physiol 286 2004 F1178 F1184
161. Q. Wang, A.A. Domenighetti, S.C. Schafer, J. Weber, A. Simon, and M.P. Maillard et al. Impact of salt on cardiac differential gene expression and coronary lesion in normotensive mineralocorticoid-treated mice Am J Physiol Regul Integr Comp Physiol 302 2012 R1025 R1033
162. D. Wang, Y.H. Liu, X.P. Yang, N.E. Rhaleb, J. Xu, and E. Peterson et al. Role of a selective aldosterone blocker in mice with chronic heart failure J Card Fail 10 2004 67 73
163. M. Wehling, C.B. Neylon, M. Fullerton, A. Bobik, and J.W. Funder Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells Circ Res 76 1995 973 979
164. M. Wehling, A. Ulsenheimer, M. Schneider, C. Neylon, and M. Christ Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: subcellular localization of calcium elevations by single cell imaging Biochem Biophys Res Commun 204 1994 475 481
165. A. Wendler, C. Albrecht, and M. Wehling Nongenomic actions of aldosterone and progesterone revisited Steroids 77 2012 1002 1006
166. C.B. Whorwood, J.A. Franklyn, M.C. Sheppard, and P.M. Stewart Tissue localization of 11 beta-hydroxysteroid dehydrogenase and its relationship to the glucocorticoid receptor J Steroid Biochem Mol Biol 41 1992 21 28
167. P. Ye, C.J. Kenyon, S.M. MacKenzie, A.S. Jong, C. Miller, and G.A. Gray et al. The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart Endocrinology 146 2005 5287 5293
168. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury N Engl J Med 357 2007 1121 1135
169. G. Yin, S. Zhao, M. Lu, N. Ma, S. Zuehlsdorff, and H. Cheng et al. Assessment of left ventricular myocardial scar in coronary artery disease by a three-dimensional MR imaging technique J Magn Reson Imaging 38 1 2013 Jul 72 79 Epub 2012 Dec 7
170. F. Yoshihara, T. Nishikimi, Y. Yoshitomi, I. Nakasone, H. Abe, and H. Matsuoka et al. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension Am J Hypertens 9 1996 523 528
171. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, and H. Shi et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21